Posts

Marengo Therapeutics and Ipsen announced Monday that they have entered into a strategic, multi-year partnership to usher two of Marengo’s precision T cell immuno-oncology candidates into the clinic.

Thursday morning, Takeda reported its quarterly sales ending June 30, 2022. The company reported a 2.4% increase in revenue for the quarter from the same period in 2021, as well as changes to its pipeline, including a decision to drop a cancer therapeutic developed with Turnstone Biologics.

Beset by clinical holds and the termination of its former company head, CytoDyn Inc. has tapped Cyrus Arman as its new president and he is expected to take over the reins of the company as chief executive officer and be added to the board of directors within six months.

Research scientists from the School of Biomedical Engineering at the University of British Columbia have found that a colony-stimulating factor 1 receptor (CSF1R) inhibitor, best known as a cancer drug, may also be a potential treatment for Duchenne muscular dystrophy (DMD), a severe genetic disorder afflicting the muscles.

Cambridge, Massachusetts’ Kendall Square just got a little more crowded. Following announcements of new facilities made by Takeda, Sanofi and life sciences giant Bayer which opened its new research and innovation center in the busy biotech hotspot known as Genetown.

Precision BioSciences entered into an exclusive global in vivo gene editing research and development collaboration and license deal with Novartis Pharma. The two companies will work to develop a potential cure for hemoglobinopathies such as sickle cell disease and beta-thalassemia.

Shares of Akero Therapeutics were surging Thursday after the company announced that pharma giant Pfizer made a $25 million equity investment that will help support the development of its experimental pre-cirrhotic and cirrhotic nonalcoholic steatohepatitis therapeutic (NASH) drug. 

Lexington, Mass.-based Aldeyra Therapeutics reported that the company’s reproxalap hit the mark in the Phase III Tranquility-2 study for dry eye disease. The drug showed statistical superiority for its two primary endpoints.

Vertex Pharmaceuticals announced on Wednesday that the U.S. Food and Drug Administration granted Breakthrough Therapy Designation to the company’s candidate, inaxaplin (VX-147). Inaxaplin was granted the designation for the treatment of APOL1-mediated focal segment glomerulosclerosis (FSGS).

Moderna Inc. said on Wednesday a new version of its coronavirus vaccine produced a better immune response against Omicron than the original shot, as the drugmaker pursues a booster against a surge in infections in the fall season.